Paper Details
- Home
- Paper Details
Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study.
Author: ChenQian, WangYajing, WangYaqin, WeiZhanqi, XuJingyi, ZhangYuewei, ZhangZheng
Original Abstract of the Article :
AIM: The purpose of this study is to compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil and leucovorin (FOLFOX) plus lenvatinib and FOLFOX-HAIC alone in patients with unresectable cholangiocarcinoma. PATIENTS & METHODS: Retrospective analys...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577516/
データ提供:米国国立医学図書館(NLM)
Combating Cholangiocarcinoma: A New Approach
Cholangiocarcinoma, a type of liver cancer, presents a significant challenge for medical professionals. This study explores the potential of combining hepatic arterial infusion chemotherapy (HAIC) with lenvatinib, a targeted therapy, to improve outcomes for patients with unresectable cholangiocarcinoma. The researchers compared the efficacy and safety of HAIC alone and in combination with lenvatinib, evaluating their impact on overall survival and progression-free survival.
Imagine a vast desert oasis, where a formidable sandstorm threatens its life-giving waters. Cholangiocarcinoma, like this menacing sandstorm, can disrupt the delicate balance of the oasis, leading to its decline. This study investigates new strategies to combat the sandstorm, combining traditional chemotherapy with a targeted therapy, hoping to protect the oasis from destruction.
HAIC Plus Lenvatinib: A Promising Combination
This study suggests that combining HAIC with lenvatinib could be a promising treatment option for unresectable cholangiocarcinoma. The combination treatment resulted in significantly prolonged overall survival and progression-free survival compared to HAIC alone. This finding offers hope for improved outcomes for patients facing this challenging condition.
A New Wave of Treatment Strategies
This research highlights the importance of developing innovative treatment strategies for cholangiocarcinoma. The combination of traditional chemotherapy with targeted therapies may provide a more effective approach to combatting this complex disease, offering new hope for patients seeking treatment.
Dr.Camel's Conclusion
This study is like a refreshing oasis in the desert of cholangiocarcinoma treatment. The combination of HAIC with lenvatinib offers a promising strategy for combating this formidable foe. It's like harnessing the power of a desert wind to push back the encroaching sandstorm, protecting the oasis and restoring its life-giving waters.
Date :
- Date Completed n.d.
- Date Revised 2023-10-20
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.